耐卡铂人卵巢癌细胞相关蛋白的筛选研究  

Study on screening the carboplatin-resistant human ovarian cancer-related protein

作　　者：冯同富[1,2] 王琪[2] 张玮[2] 黎丹戎[2] 李力[2] 

机构地区：[1]湖北省妇幼保健院妇科,武汉430000 [2]广西医科大学附属肿瘤医院肿瘤妇科,南宁530021

出　　处：《药物不良反应杂志》2010年第6期387-392,共6页Adverse Drug Reactions Journal

基　　金：广西自然科学基金资助项目(0991234);广西壮族自治区大型仪器协作共用网资助项目

摘　　要：目的:筛选耐卡铂人卵巢癌细胞相关蛋白质,从蛋白质水平探讨耐药的分子机制。方法:提取人卵巢癌亲代细胞SKOV3和对卡铂耐药的细胞SKOV3/CB的总蛋白,用二维液相色谱技术分离、筛选二者之间的差异蛋白,用电喷雾离子阱质谱技术分析鉴定蛋白质。结果:共分离筛选出差异蛋白54个,其中SKOV3细胞系表达上调者20个,SKOV3/CB细胞系表达上调者34个。初步鉴定出SKOV3/CB细胞系4个表达上调的耐药相关差异蛋白,即超氧化物歧化酶1、周期蛋白依赖激酶6抑制因子、转录适配蛋白1和垂体腺苷酸环化酶促多肽。这些蛋白涉及氧化还原、细胞周期调控及凋亡等多方面。结论:人卵巢癌对卡铂耐药的机制可能与多种蛋白质有关;有关实验数据对进一步研究人卵巢癌对铂类的耐药有一定价值。Objective： To screen carboplatin-resistant human ovarian cancer-related protein in order to explore the molecular mechanism of resistance at the protein level.Methods： The total proteins of parental（SKOV3） and carboplatin-resistant（ SKOV3/CB） cell lines derived from human ovarian cancer were extracted,the differentially expressed proteins were separated and screened by two-dimensional liquid chromatography.The proteins were identified by electrospray ionization-tandem mass spectrometry（ESI-MS/MS）.Results： A total of 54 differentially expressed proteins were isolated and screened.Of these proteins,the expression of 20 proteins were up-regulated in SKOV3 cell line and the expression of 34 proteins were up-regulated in SKOV3/CB cell line.Four proteins whose expression were upregulated in SKOV3/CB cell line associated with carboplatin resistance were identified,including superoxide dismutase,cyclin-dependent kinase 6 inhibitor,transcriptional adapter 1 protein,and proapoptotic caspase adapter protein.These proteins were associated with oxidation and reduction, cell cycle control,apoptosis and others.Conclusion： The mechan ism of carboplatin resistance in the human ovarian cancer may be related to different kinds of proteins;and these experimental data will be valuable for further study of platinum resistance in the human ovarian cancer.

关 键 词：卵巢肿瘤 铂类耐药 差异蛋白 二维液相分离 

分 类 号：R737.31[医药卫生—肿瘤]